Sign in
TRML Stock Price, Chart, Stats & News
Tourmaline Bio, Inc.
Save
1.23B
Market cap
–
Current P/E
–
Forward P/E
TRML chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -5.00% |
Operating margin | -256122.50% |
Pretax margin | -221185.00% |
Net margin | -221185.00% |
Effective tax rate | – |
ROA | -32.85% |
ROE | -30.50% |
D/E | 0.00x |
Interest coverage ratio | – |
TRML valuation
P/E | – |
P/S | 30816.28x |
P/B | 4.77x |
P/CF | -14.32x |
P/FCF | -14.28x |
P/OCF | -14.32x |
PEG | 2.04x |
EV multiple | -13.22x |
About
Tourmaline Bio, Inc. is a clinical-stage biotechnology firm committed to advancing therapies for individuals suffering from debilitating immune disorders. The company's development pipeline focuses on conditions such as Atherosclerotic Cardiovascular Disease (ASCVD) and Thyroid Eye Disease (TED). Established in 2021, this enterprise is headquartered in New York, New York.
Similar securities
Based on sector and market capitalization
Report issue